

2026		
CRA Trainer	CRA's support and development through virtual monitoring Action Site	
Monitor	Cardiology (Coronary Artery Disease), drug and device study, Switzerland, 1 site: site management and monitoring	Cardiology (PFO), device study, 2 sites, France : site management and monitoring
	Hematology (phase 1/2 Central Nervous System Lymphoma), biotechnology company France 4 sites: site management and monitoring	
LCRA	Hematology (phase 2) 8 CRA across 4 EU countries, CTIS submission, investigational site's contract, vendors management, study documents and study plans review	

2025		
Clinical Trial Manager	Hematology (phase 2) CTIS submission, investigational site's contract, LCRA activities (8 CRA across 4 EU countries), vendors management, study documents and study plans review	
CRA Trainer	CRA's support and development through virtual monitoring Action Site	
CRA	Hematology (phase 1/2 Central Nervous System Lymphoma), biotechnology company France 4 sites: initiation, site management and monitoring	Lung Cancer (Non-Small Cell Lung Cancer) phase 1/2, biotechnology company France 3 sites: initiation, site management and monitoring

2024		
CRA Trainer	CRA's support and development	
CRA	Hematology (phase 1/2 Leukemia, Myelodysplastic syndrome), biotechnology company France 3 sites: initiation, site management and monitoring	Hematology (phase 1/2 Central Nervous System Lymphoma), biotechnology company France 4 sites: initiation, site management and monitoring
	Lung Cancer (Non-Small Cell Lung Cancer) phase 1, biotechnology company France 3 sites: initiation, site management and monitoring	Ovarian Cancer (Low-Grade Serous Ovarian Cancer) phase 3, biotechnology company France 6 sites: initiation, site management and monitoring

2023		
Clinical Trial Manager	Ophthalmology (phase 3), pharmaceutical company 20 sites, 360 patients: vendors management, submission packages review, study documents and study plans review, CRA team management (10 CRA across 5 EU countries)	
Lead CRA	Oncology and Hematology (phase 3 DLBCL, phase 1 ovarian and uterus cancer), biotechnology company LCRA activities 21 CRA across 11 EU countries, support to Project Lead, assessment of CRA	
CRA	Hematology (phase 1/2 Leukemia, Myelodysplastic syndrome, Lymphoma), biotechnology company France 4 sites: initiation, site management and monitoring	
	Hematology (phase 1/2 Leukemia, Myelodysplastic syndrome), biotechnology company France 3 sites: initiation, site management and monitoring	Hematology (phase 1/2 Central Nervous System Lymphoma), biotechnology company France 1 site: initiation

2022

Project Manager	Ophthalmology (clinical investigation medical device), medical device and pharmaceutical company 6 sites, 100 patients: protocol and study documents development	
Lead CRA	Oncology and Hematology (phase 3 DLBCL, phase 1 ovarian and uterus cancer), biotechnology company LCRA activities 21 CRA across 11 EU countries, support to Project Lead, assessment of CRA	
Study Start Up Specialist	France Phase 3: amendments submission to ethics committee France Phase 1: study initial submission to ethics committee, Data privacy, site contracts including CNOM.	France Medical Device clinical investigation: initial submission ethics committee and competent authority
Medical writer	Ophthalmology (clinical survey): poster and manuscript development	

2021			
Project Manager	Ophthalmology (clinical survey), medical device and pharmaceutical company 100 sites, 3500 patients: protocol and study documents development, regulatory package (data privacy), project daily management		
Lead CRA	Oncology and Hematology (phase 3 DLBCL, phase 2 colorectal cancer), biotechnology company LCRA activities 21 CRA across 11 EU countries, support to Project Lead, assessment of CRA		
Study Start Up Specialist	France Phase 2 study initial submission and amendments: ethics committee, Data privacy, site contracts including CNOM.	Phase 3: site contracts including CNOM.	
	France Phase 1 study initial submission and amendments: ethics committee, Data privacy, site contracts including CNOM.		
CRA	Oncology (phase 2 colorectal cancer), biotechnology company France 5 sites: site initiation and monitoring	Hematology (phase 3 DLBCL), biotechnology company France 8 sites: site initiation and monitoring	
	Oncology (phase 1 bladder cancer), biotechnology company France 1 site: site initiation		
2020			
Project Manager	PMCardiology (observational global study, rare disease), academic society 40 countries Europe, 130 sites, 1.000 subjects: protocol development, start-up activities, and project conduct up to report and publication.		Cardiology (observational prospective study), academic society 70 countries worldwide, 360 sites, 10.000 subjects: protocol development, start-up activities and project conduct up to report and publication.
	Orthopedics (observational study medical device), medical device company 2 sites, 60 subjects, France: protocol development, start-up activities and project conduct up to report		
Study Start Up Specialist	France, observational study initial submission and amendment: ethics committee, French Data privacy, Notification to ANSM, site contracts including CNOM.		UK observational study initial submission and amendment: ethics committee, HRA, site contracts, UK portfolio adoption
	Phase 2 study initial submission and amendments: French ethics committee, French Data privacy, site contracts including CNOM.		
CRA	Neurology (phase 3 insomnia), international CRO France 3 sites: monitoring and site closure	Oncology (phase 2 colorectal cancer), biotechnology company France 5 sites: site initiation and monitoring	Hematology (phase 3 DLBCL), biotechnology company France 14 sites: site selection
2019			
Project Manager	Cardiology (observational global study, rare disease), academic society 40 countries Europe, 130 sites, 1.000 subjects: protocol development, start-up activities, and project conduct up to report and publication.		Cardiology (observational prospective study), academic society 70 countries worldwide, 360 sites, 10.000 subjects: protocol development, start-up activities and project conduct up to report and publication.
Study Start Up Specialist	France, phase 1 and phase 3 studies, initial submission to ethics committee	France, observational study initial submission and amendment: ethics committee, French Data privacy, Notification to ANSM, site contracts including CNOM.	UK observational study initial submission and amendment: ethics committee, HRA, site contracts, NIHR UK portfolio adoption

Project Manager	Cardiology (observational global study, rare disease), academic society 40 countries Europe, 130 sites, 1.000 subjects: protocol development, start-up activities, and project conduct up to report and publication.	Cardiology (observational prospective study), academic society 70 countries worldwide, 360 sites, 10.000 subjects: protocol development, start-up activities and project conduct up to report and publication.
CRA	Neurology (phase 3 insomnia), international CRO France 3 sites: monitoring	

2018

Project Manager	Cardiology (observational global study, rare disease), academic society 40 countries Europe, 130 sites, 1.000 subjects: protocol development, start-up activities, and project conduct up to report and publication.		Cardiology (observational prospective study), academic society 70 countries worldwide, 360 sites, 10.000 subjects: protocol development, start-up activities and project conduct up to report and publication.	
	Orthopedics (clinical investigation medical device), medical device company 2 sites, 100 subjects: protocol development, start-up activities and project conduct up to report		Ophthalmology (observational prospective study), medical device and pharmaceutical company 4 sites, 60 subjects: protocol development, start-up activities (site selection, contract, submissions for authorization) and project conduct	
Study Start Up Specialist	UK Phase 3 initial submission: ethics committee, HRA, competent authorities, site contracts UK, NIHR portfolio adoption	Germany Phase 3 initial submission ethics committees	France Phase 3 and medical device initial submissions: ethics committee, French Data privacy, site contracts including CNOM.	Belgium Medical device initial submissions Ethics Committees
CRA	Neurology (phase 3 insomnia), international CRO France 3 sites: site selection, monitoring	Neurology (phase 3 ICU), international CRO France 10 sites: site selection	Cardiology (phase 3, HTA) France 8 sites: site selection	
Medical writer	Clinical Evaluation Reports (orthopedic medical devices)			

2017

Project Manager	Cardiology (observational global study, rare disease), academic society 40 countries Europe, 130 sites, 1.000 subjects: protocol development, start-up activities, and project conduct up to report and publication.		Cardiology (observational prospective study), academic society 70 countries worldwide, 360 sites, 10.000 subjects: protocol development, start-up activities and project conduct up to report and publication.	
	Ophthalmology (market survey), pharmaceutical company 4 sites, 1000 patients, protocol questionnaire, authorization (data privacy), conduct, data analysis, poster and publication		Ophthalmology (clinical investigation medical device), medical device and pharmaceutical company 3 sites, 50 subjects: protocol development and project conduct up to report	
Study Start Up Specialist	France food supplement and medical device: submission ethics committee, competent authorities, French Data privacy, site contracts including CNOM.	UK Medical device initial submission: ethics committee, HRA, and competent authorities	Germany Phase 3 initial submission ethics committees	
Medical writer	Clinical Evaluation Reports (orthopedic medical devices)		Expert scientific report: cosmetic ingredient, pre-clinical and clinical data	
	Market survey, ophthalmology: communication (paper accepted in Journal Français d'Ophthalmologie Sep. 2017, oral communication for KOL at Société Française d'Ophthalmologie May 2016 and poster)		Development of pediatric consents	

2016				
Project Manager	Cardiology (observational global study, rare disease), academic society 40 countries Europe, 130 sites, 1.000 subjects: protocol development, start-up activities, and project conduct up to report and publication.		Cardiology (observational prospective study), academic society 70 countries worldwide, 360 sites, 10.000 subjects: protocol development, start-up activities and project conduct up to report and publication.	
	Ophthalmology (market survey), pharmaceutical company Protocol questionnaire, authorization (data privacy), conduct, data analysis, poster and publication			
CRA	Oncology (phase 2 head neck cancer) international CRO 3 sites, France: monitoring	Hematology (phase 2), international CRO 5 sites, France: site selection	Immunology (phase 2), international CRO 4 sites, France: site selection	Rheumatology (phase 3), international CRO 5 sites, France: site selection
Regulatory consultant	External consultant for French Competent Authorities (ANSM)			
Study Start Up Specialist	France Phase 2 initial submission ethics committee and competent authorities, French Data privacy, site contracts including CNOM.		UK Phase 2 initial submission ethics committee, HRA and competent authorities	
Scientific communication	Expert board, medical device: data analysis, presentation development			

2015				
Project Manager	Cardiology (observational global study, rare disease), academic society 40 countries Europe, 130 sites, 1.000 subjects: protocol development, start-up activities, and project conduct up to report and publication.		Cardiology (observational prospective study), academic society 70 countries worldwide, 360 sites, 10.000 subjects: protocol development, start-up activities and project conduct up to report and publication.	
CRA	Oncology (phase 2 head neck cancer) international CRO 3 sites, France: monitoring			
Study Start Up Specialist	Germany Observational study initial submission ethics committee.	UK Observational study initial submission ethics committee. HRA	France Phase 1 initial submission ethics committee and competent authorities	Belgium Phase 1 initial submission ethics committee and competent authorities
Regulatory consultant	External consultant for French Competent Authorities (ANSM)			

2014				
CRA	Oncology (phase 2 colorectal cancer), biotechnology company France 3 sites: monitoring		Orthopedics (non-interventional study), medical device company France 2 sites: site management and monitoring	
Study Start Up Specialist	France Medical device and phase 4 pass studies initial submission ethics committee and competent authorities	UK Phase 4 pass study initial submission ethics committee, HRA and competent authorities	Italy Phase 4 pass study initial submission ethics committees	
Scientific communication	Expert board, medical device, prosthesis: data analysis, presentation development		Expert board, drug, vaccines: support development, minutes and follow up.	

2013

CRA	Oncology (phase 2 colorectal cancer), biotechnology company France 3 sites: monitoring	Orthopedics (non-interventional study), medical device company France 2 sites: site management and monitoring
Learning	Pharmaceutical company: development of training supports for standard operating procedures	Clinical regulation intelligence: training of clinical team on updated trial regulation in France.

2010-2013

Clinical Project Manager	Galderma
--------------------------	----------

2007-2010

Clinical Operation Coordinator	Sanofi Pasteur MSD
--------------------------------	--------------------

2000-2007

CRA	BRISTOL MYERS SQUIBB CHU SANT ETIENNE
-----	--